Study of the gastroenteropancreatic neuroendocrine tumor (gep-net) microenvironment beyond angiogenesis: The role of lysyl oxidase-like 2 (LOXL2).

Jorge Barriuso(Queen's University Belfast), Marta Mendiola(Hospital Universitario La Paz), Daniel Castellano(Universidad Complutense de Madrid), Enrique Grande(MD Anderson Cancer Center Madrid), Laura Guerra(Hospital Universitario La Paz), Cristina Álvarez‐Escolá(Hospital Universitario La Paz), Jaime Martinez(John H. Stroger, Jr. Hospital of Cook County), Jaume Capdevila(Vall d'Hebron Hospital Universitari), Esther Díaz, Emilio Burgos(Hospital Universitario Infanta Sofía), Jaime Feliú(Hospital Universitario La Paz), Elsa Bernal, Jose Castell(Hospital Universitario La Paz)
Journal of Clinical Oncology
May 20, 2014
10.1200/jco.2014.32.15_suppl.4109
Cited by 0

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2017|1.3k